CD8/PD-L1 dual IHC, quality control; co-registration; details of the automated classification assessment; details of digital IA scoring solutions; measurement of CD8+ TILs in PD-L1âpositive tumor. (DOCX 45Â kb
Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb
Figure S1. Representative staining patterns of FFPE GBC lesions with CD133-specific mono antibody. C...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...
Table S1 Relevant image information for nonclinical sample sets. Table S2 Nonclinical tumor samples,...
Figure S1 IA classification of CD8+ lymphocytes. Figure S2 IA classification of elongate CD8+ lympho...
Figure S1. Comparison of CD8 levels in PD-L1 negative and positive groups. A & B: Comparison of CD8 ...
Figure S1. Immunohistochemically staining of PD-L1 proteins in patients with hepatocellular carcinom...
Figure S1 Digital image analysis segments CD8+ and PD-L1+ cells in dual-labelled sections of NSCLC. ...
Table S1. CD8 levels distribution according to tumor subtype and clinicopathological features. (DOCX...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
Schematic representation of process for TIL initiation, expansion and testing. Figure S2. Lymphocyti...
IHC analysis of human CD4-, CD3-, CD8-, CD20-, CD68-, CD4-, and CD8-positive cells present in BCM-21...
Figure S2. Immunohistochemically staining of CD8 proteins in patients with hepatocellular carcinoma....
Abstract Background Immuno-oncology and cancer immunotherapies are areas of intense research. The nu...
Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb
Figure S1. Representative staining patterns of FFPE GBC lesions with CD133-specific mono antibody. C...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...
Table S1 Relevant image information for nonclinical sample sets. Table S2 Nonclinical tumor samples,...
Figure S1 IA classification of CD8+ lymphocytes. Figure S2 IA classification of elongate CD8+ lympho...
Figure S1. Comparison of CD8 levels in PD-L1 negative and positive groups. A & B: Comparison of CD8 ...
Figure S1. Immunohistochemically staining of PD-L1 proteins in patients with hepatocellular carcinom...
Figure S1 Digital image analysis segments CD8+ and PD-L1+ cells in dual-labelled sections of NSCLC. ...
Table S1. CD8 levels distribution according to tumor subtype and clinicopathological features. (DOCX...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
Schematic representation of process for TIL initiation, expansion and testing. Figure S2. Lymphocyti...
IHC analysis of human CD4-, CD3-, CD8-, CD20-, CD68-, CD4-, and CD8-positive cells present in BCM-21...
Figure S2. Immunohistochemically staining of CD8 proteins in patients with hepatocellular carcinoma....
Abstract Background Immuno-oncology and cancer immunotherapies are areas of intense research. The nu...
Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb
Figure S1. Representative staining patterns of FFPE GBC lesions with CD133-specific mono antibody. C...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...